Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00353) | |||||
---|---|---|---|---|---|
Name |
Lenalidomide
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
Lenalidomide; 191732-72-6; Revlimid; Revimid; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; CC-5013; Lenalidomide (CC-5013); CDC 501; CC 5013; CDC-501; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Revlimid (TN); CHEBI:63791; C13H13N3O3; MFCD07772307; 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; NCGC00167491-01; 3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione; DSSTox_CID_26664; DSSTox_RID_81806; DSSTox_GSID_46664; Revlimid (lenalidomide); 3-(4-Amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione; CAS-191732-72-6; Lenalidomide (USAN/INN); Lenalidomide [USAN:INN:BAN]; (3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; ENMD 0997; ENMD-0997; HSDB 8220; IMID-5013; CDC-5013; ALBB-015321; PubChem19113; CHEMBL848; Revlimid (TN) (Celgene); SCHEMBL32978; MLS003899194; GTPL7331; SCHEMBL1980410; 3-(4-Amino-1-oxo-2-isoindolinyl)piperidine-2,6-dione; DTXSID8046664; BDBM65454; 2,6-piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, (3S)-; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; BCPP000186; HMS3654G07; HMS3674C05; BCP01390; HY-A0003; Revlimid, Lenalidomide, CC-5013; SYP-1512; Tox21_112492; ABP001089; AC-914; NSC747972; STK639603; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-; AKOS005146276; AKOS005174869; Tox21_112492_1; ACN-034469; BCP9000847; CCG-264781; CS-0125; DB00480; KS-1207; MCULE-9771679074; NSC-747972; NCGC00167491-02; NCGC00167491-03; NCGC00167491-04; AK-47482; BR-47482; SMR002529986; SY047646; AB0017965; AM20050439; FT-0659651; FT-0670758; FT-0670759; SW218084-2; EC-000.2340; D04687; S-4172; AB01273975-01; AB01273975-02; AB01273975_03; 732L726; Q425681; SR-01000883999; Q-101410; SR-01000883999-1; Z1741976709; 2, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-; 3-(4-amino-1,3-dihydro-1-oxo-2h-isoindol-2-yl)-2,6-piperidinedione; 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-dioxopiperidine; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-piperidinedione; 443912-14-9
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Sickle cell anaemia | ICD-11: 3A51 | [1] | ||
PubChem CID | |||||
Formula |
C13H13N3O3
|
||||
Canonical SMILES |
C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
|
||||
InChI |
1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
|
||||
InChIKey |
GOTYRUGSSMKFNF-UHFFFAOYSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=216326"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 259.26 | Topological Polar Surface Area | 92.5 | |
XlogP | -0.5 | Complexity | 437 | ||
Heavy Atom Count | 19 | Rotatable Bond Count | 1 | ||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Lenalidomide 10 mg capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Celgene Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [2] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [2] | |||
Lenalidomide 15 mg capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Celgene Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [2] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [2] | |||
Lenalidomide 2.5 mg capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Celgene Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [2] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [2] | |||
Lenalidomide 20 mg capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Celgene Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [2] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [2] | |||
Lenalidomide 25 mg capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Celgene Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [2] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [2] | |||
Lenalidomide 5 mg capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Magnesium stearate; Croscarmellose sodium; Cellulose, microcrystalline
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Celgene Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [2] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [2] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.